Analyst Ratings For NASDAQ:LIFE – aTyr Pharma (NASDAQ:LIFE)
Today, Piper Jaffray reiterated its Overweight rating on NASDAQ:LIFE – aTyr Pharma (NASDAQ:LIFE) with a price target of $3.00.
Some recent analyst ratings include
- 5/14/2018-Piper Jaffray Reiterated Rating of Overweight.
- 2/14/2018-JPMorgan Chase was Downgraded by analysts at JPMorgan Chase from a “Neutral ➝ Underweight” rating to a “” rating.
Recent Insider Trading Activity For NASDAQ:LIFE – aTyr Pharma (NASDAQ:LIFE)
NASDAQ:LIFE – aTyr Pharma (NASDAQ:LIFE) has insider ownership of 25.00% and institutional ownership of 58.91%.
- On 2/8/2018 Ashraf Amanullah, Insider, sold 1,402 with an average share price of $3.40 per share and the total transaction amounting to $4,766.80.
- On 8/31/2017 John Mendlein, CEO, bought 37,736 with an average share price of $2.65 per share and the total transaction amounting to $100,000.40.
- On 8/31/2017 Paul Schimmel, Director, bought 94,336 with an average share price of $2.65 per share and the total transaction amounting to $249,990.40.
- On 4/24/2017 John Mendlein, CEO, bought 124 with an average share price of $3.00 per share and the total transaction amounting to $372.00.
- On 4/20/2017 John Mendlein, CEO, bought 2,552 with an average share price of $3.00 per share and the total transaction amounting to $7,656.00.
- On 12/21/2016 Paul Schimmel, Director, bought 25,000 with an average share price of $2.28 per share and the total transaction amounting to $57,000.00.
- On 12/20/2016 Ashraf Amanullah, VP, bought 11,000 with an average share price of $2.25 per share and the total transaction amounting to $24,750.00.
Recent Trading Activity for NASDAQ:LIFE – aTyr Pharma (NASDAQ:LIFE)
Shares of NASDAQ:LIFE – aTyr Pharma closed the previous trading session at 1.77 down -0.53 23.20% with 2.299999952316284 shares trading hands.